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Na+,K+-ATPase is a membrane-spanning protein which transports
Na+-ions to the outside and K+-ions to the inside of the cell at the
expense of ATP, and thus maintains sodium and potassium
homeostasis in animal cells (Lingrel and Kuntzweiler, 1994; Rose
and Valdes, 1994). Na+,K+-ATPase consists of an a-subunit and a
b-subunit present in a 1:1 molar ratio. Up till now, three a- and
three b-subunit types have been identified. Different a-subunits
can combine with different b-subunits to form bioactive
Na+,K+-ATPase. Although the a-subunit is the catalytic subunit of
Na+,K+-ATPase, its assembly with a b-subunit in the endoplasmic
reticulum is a prerequisite for stable expression, full function and
transport to the cell membrane (Geering, 1990; McDonough et al,
1990).
The Na+,K+-ATPase generated electrochemical gradient is
responsible for transport of several compounds over the cell
membrane. The uptake of cisplatin, a chemotherapeutic agent that
has been used in the treatment of hormone-refractory prostate
cancer (Akimoto et al, 1994; Coughlin et al, 1994; Sakai et al,
1994; Veronesi et al, 1996), is also regulated in a number of cell
systems by Na+,K+-ATPase. Andrews et al. (1991) describe the
inhibition of cisplatin uptake by treatment of ovarian carcinoma
cells with ouabain, a specific inhibitor of Na+,K+-ATPase activity.
Shinohara et al (1994) reported that low levels of Na+,K+-ATPase
would protect NIH/3T3 cells against cisplatin-induced apoptosis.
Furthermore, a link was made between low levels of expression of
Na+,K+-ATPase and insensitivity to cisplatin in non-small-cell
lung cancer cells (Ohmori et al, 1994; Kasahara et al, 1996; Bando
et al, 1997). Bando et al (1998a, 1998b), however, reported that in
small-cell lung cancer cells this correlation could not be made.
In search for genes that are potentially involved in the transition
from hormone-dependent to hormone-independent prostate cancer
cell growth, the b1-subunit of Na+,K+-ATPase was identified. In
the current study it is shown that expression of the b1-subunit of
Na+,K+-ATPase is increased in hormone-independent human
prostate cancer xenografts. Furthermore, it is shown that andro-
gens are potent inhibitors of Na+,K+-ATPase activity in androgen-
dependent prostate cancer cells.
A problem in the treatment of prostate cancer is that 50% of
men, treated for what seemed to be confined prostate cancer,
actually already have advanced prostate cancer. Advanced prostate
cancer can initially be treated effectively by androgen ablation
therapy, but eventually will evolve into androgen-independent
prostate cancer. The reason metastatic disease can develop is that
the initial treatment of prostate cancer was not effective in
removing (surgery) or destroying (irradiation) all prostate cancer
cells. At this moment much attention is drawn to develop adjuvant
treatment modules to remove cancer cells remaining after the
initial treatment (Schnidt et al, 1993; Oliver and Gallagher, 1995;
Nelson and Simons, 1996; Chao et al, 1997).
In the current study, investigations were also performed to test
the hypothesis that decreased Na+,K+-ATPase expression or
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activity in prostate cancer cells would result in reduced sensitivity
to cisplatin treatment. The latter investigations may be relevant for
improving the effectiveness of treatment of prostate cancer using
chemotherapeutic agents.
MATERIALS AND METHODS
Cells
The LNCaP-FGC cell line is a gift from Dr JS Horoszewicz
(Buffalo, NY, USA) and is identical to the LNCaP cell line which
is provided by ATCC (Horoszewicz et al, 1983). For maintenance,
these cells were cultured in RPMI-1640 supplemented with 7.5%
fetal calf serum (FCS) in the presence of antibiotics. For the
experiments, cells were passaged into RPMI-1640 supplemented
with 5% stripped serum (dextran-coated charcoal-treated FCS
(dcc-FCS)) and were cultured for the indicated times with or
without hormones. LNCaP-FGC cells are referred to as androgen-
dependent cells, although, in the absence of androgens, these cells
will not undergo apoptosis and may even show slow growth
(Chang et al, 1997). LNCaP-FGC cells were used between
passages 29 and 36. LNCaP-LNO cells (also provided to us by
Dr JS Horoszewicz) originate from an early passage of the
LNCaP-FGC cells, and grow in RPMI-1640 supplemented with
5% dcc-FCS. LNCaP-LNO cells were used between passages
45 and 50. Concentrations of R1881, vitamin D3, ouabain (Sigma,
St Louis, MO, USA) and cisplatin (cis-Platinum(II)diamine
Dichloride, Sigma) which were added to the culture media, are
indicated in the legends to the Figures.
Human prostate cancer xenografts
Tumour specimens, obtained from primary carcinomas, metastatic
lesions and transurethral resection, were implanted subcuta-
neously (s.c.) into both shoulders of NMRI male nude mice. All
animals had been castrated and supplemented with testosterone
before surgery, in order to ensure a similar endocrine background
for all tumours. The human prostate cancer xenograft panel used
for these investigations contained four androgen-responsive
(PC-82, PC-295, PC-310 and PC-346) and five androgen-indepen-
dent tumours (PC-133, PC-135, PC-324, PC-339 and PC-374).
Among the androgen-responsive human prostate cancer
xenografts, three xenografts (PC-82, PC-295 and PC-310) are
fully dependent on androgens for growth, while one xenograft
(PC-346) shows a heterogeneous response when androgens are
withdrawn from the tumour-bearing mice. The tumours retained
their resemblance to the original patient material, and their main
characteristics have been described (van Weerden et al, 1996).
Differential display PCR
Differential display polymerase chain reaction (ddPCR) was origi-
nally performed to detect differences in mRNA expression
between the androgen-dependent LNCaP-FGC prostate cancer cell
line and the androgen-independent LNCaP-LNO cell line. As
outlined in detail by Chang et al (1997), R1881 and vitamin D3
were added in order to obtain similar growth characteristics in
both cell lines. LNCaP-FGC and LNCaP-LNO cells were cultured
for 6 days in the presence or absence of R1881 (0.1 nM, 10 nM),
vitamin D3 (100 nM) or a combination of the two hormones (10 nM
R1881 + 100 nM vitamin D3). The biologically active vitamin D
metabolite 1,25(OH)2D3 was a gift from Dr L Binderup (Leo
Pharmaceutical Products, Ballerup, Denmark) and was donated to
us by Dr JPTM van Leeuwen (Department of Internal Medicine,
Erasmus University Rotterdam, The Netherlands). Total RNA was
isolated and using a random primer (5¢-GCAAGCTTGCTA-
CAACGAGG-3¢ [Pharmacia Biotech, Roosendaal, The
Netherlands]) cDNA was generated (MMLV-reverse transcriptase;
Life Technologies, Breda, The Netherlands). The cDNA was used
in a PCR reaction (Super Taq, Biotechnology Ltd, Cambridge,
UK) using the same primer in the forward and reverse reaction in
the presence of 32P-dATP (Amersham, Buckinghamshire, UK).
Further details are described by Chang et al (1997).
RNA isolation and hybridization
Total RNA was isolated and electrophoresed as described by
Blok et al (1995). As a probe to detect the b1-subunit of
Na+,K+-ATPase, a 191 bp differential display PCR-fragment was
used. For PSA mRNA detection, a previously isolated 266 bp
differential display PCR-fragment (Blok et al, 1995) was used.
The  b-actin probe represents a 1.1 kb Pst1-fragment from
hamster  b-actin.
Western blot
LNCaP-FGC cells were cultured in RPMI-1640 + 5% dcc-FCS in
the presence or absence of 0.1 nM R1881. Subsequently, the cells
were lysed and equal amounts of protein were loaded onto a
sodium dodecyl sulphate (SDS)-containing polyacrylamide gel,
electrophoresed and blotted onto nitrocellulose. A goat polyclonal
antibody raised against rabbit a1—b1 Na+,K+-ATPase (Peters et al,
1984; 500-fold diluted) and a peroxidase-conjugated rabbit anti-
goat antibody (1:4000 dilution, Sigma) were used to detect
Na+,K+-ATPase by chemiluminescense.
Ouabain binding analysis
LNCaP-FGC cells were cultured to 50% confluence in RPMI-
1640 + 5% dcc-FCS in the presence or absence of 0.1 nM R1881.
After 3 days the medium was renewed and after 6 days the
medium was changed for incubation buffer (40 mM imidazole,
pH 7.3, 250 mM sucrose, 5 mM magnesium chloride) containing
different amounts of 3H-ouabain (2.5 nM, 5 nM, 10 nM, 20 nM,
40 nM, 80 nM) in the presence or absence of 500-fold non-labelled
ouabain.  3H-ouabain was obtained from Amersham. The cells
were incubated with 3H-ouabain for 2 h at 37°C. Subsequently, the
cells were washed four times with incubation buffer at 0°C, before
being lysed in 0.5 M sodium hydroxide (NaOH) for 45 min at
56°C. Samples (50 ml) were counted using liquid scintillation and
protein concentrations were measured using Bradford￿s reagent.
Scatchard plots were constructed and Kd and  Bmax values
calculated.
Ouabain/cisplatin incubations
Toxicity of ouabain was measured, after 8 days of culture in a
12-well tissue culture plate in the presence of different concentra-
tions of ouabain, by incubating the cells for 30 min at 37°C with
nitro blue tetrazolium (NBT; Sigma) (100 mM phosphate pH 7.4,
0.2 mg ml—1 NBT, 0.4 mg ml—1 NADH). Mitochondrial diaphorase
in cells with ruptured membranes will reduce NBT to NBTH2,
a blue-coloured precipitate.30 LJ Blok et al
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Toxicity of cisplatin was measured after 8 days of culture
(which was found to be an optimal time point) of the LNCaP-FGC
cells in the presence or absence of different concentrations of
cisplatin. Cells were washed once in phosphate-buffered saline
(PBS) to remove dead cells and debris. Subsequently, the cells
were lysed in 1 M NaOH for 45 min at 56°C and DNA concentra-
tions were measured (Chang et al, 1997). In order to determine
whether LNCaP-FGC cell death has characteristics of apoptosis or
necrosis when exposed to cisplatin, staining of DNA with Hoechst
33342 and propidium iodide (PI) was performed (Darzynkiewicz
et al, 1994). Hoechst 33342 can enter living cells and stain the
DNA blue when exposed to 352 nm light. In apoptotic cells the
condensed chromatin stains very intense. PI can only stain the
DNA of cells with disrupted cellular (plasma and nuclear)
membranes. Using this dye, DNA stains red when exposed to
530 nm light. In early apoptotic cells, PI cannot enter the cell, in
contrast to late apoptotic cells where the cellular membrane is no
longer intact and PI stains the condensed chromatin very intensely.
When a cell is necrotic, both Hoechst 33342 and propidium iodide
will enter the cell and stain DNA. However, in necrotic cells, the
chromatin is not condensed and will only stain diffusely blue and
red using Hoechst 33342 and PI respectively (Darzynkiewicz et al,
1994). This method, to make a distinction between apoptotic and
necrotic cells after cisplatin treatment, was also used by Lieberthal
et al (1996).
RESULTS
Differential expression of the b1-subunit of
Na+,K+-ATPase
Differential display PCR was performed to identify differences in
mRNA expression between the androgen-dependent LNCaP-FGC
and the androgen-independent LNCaP-LNO cell line (Chang et al,
1997). Clone 8 was detected as a differentially expressed cDNA
between the two cell lines. After cloning the PCR fragment into an
appropriate vector, it was established by sequencing that clone 8
was 191 bp in length. When the sequence of clone 8 was compared
to known sequences present in the NIH/EMBL databases a
100% homology at the nucleotide level to the b1 subunit of
Na+,K+-ATPase was found (fragment 560—751, Ruiz et al, 1995).
When mRNA expression of the b1-subunit of Na+,K+-ATPase was
analysed on Northern blots in order to verify the ddPCR results, it
was observed that under control culture conditions (no hormones
added) the expression levels in LNCaP-FGC and LNCaP-LNO
cell lines were similar. However, when hormones were added, the
b1-subunit of Na+,K+-ATPase was found to be markedly down-
regulated by androgens (0.1 nM and 10 nM R1881) and by vitamin
D3 (100 nM). Furthermore, androgen-induced down-regulation of
mRNA expression of the b1-subunit of Na+,K+-ATPase in the
androgen-dependent LNCaP-FGC cells was much more
pronounced than in androgen-independent LNCaP-LNO cells
(Figure 1).
In human prostate cancer xenografts (grown in testosterone-
supplemented castrated nude mice) the expression of the
b1-subunit of Na+,K+-ATPase mRNA was low in the four
androgen-responsive xenografts (PC-82, PC-295, PC-310 and
PC-346). Interestingly, in four out of five androgen-independent
xenografts (PC-133, PC-324, PC-339 and PC-374), the expression
of  b1-subunit mRNA was markedly higher (Figure 2). For
unknown reasons, the androgen-independent xenograft PC-135
forms an exception because of its low b1-subunit mRNA expres-
sion. As indicated, the xenografts were grown in the presence of
testosterone and the findings correlate well with the observed
differential expression of the b1-subunit between LNCaP-FGC
and LNCaP-LNO cells when these cells were cultured in the
presence of androgens (Figure 1, compare LNCaP-FGC lanes 2
and 3 with LNCaP-LNO lanes 2 and 3). A correlation was also
observed between the expression of b1-subunit of Na+,K+-ATPase
and glandular differentiation of the xenografts; glandular differen-
tiation of the androgen-responsive xenografts varies from well to
moderately-well with the expression of the b1-subunit being
low, and glandular differentiation of the androgen-independent
xenografts ranges from moderate to poor while the expression of
the  b1-subunit is high (Figure 2). The androgen-responsive
PC-346 is an exception having low b1-subunit mRNA expression
and poor glandular differentiation.
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Figure 1 Expression of the b1-subunit of Na+,K+-ATPase in androgen-
dependent LNCaP-FGC and androgen-independent LNCaP-LNO cells.
LNCaP-FGC (top 5 lanes) and LNCaP-LNO (bottom 5 lanes) cells were
cultured for 6 days in the absence (Control) or presence either of 0.1 nM
R1881, 10 nM R1881, 100 nM Vitamin D3 (Vit D3) or 100 nM Vitamin D3 +
10 nM R1881 (Vit D3 + R1881). Cells were harvested and total RNA isolated.
Total RNA was loaded on a denaturing gel (20 mg per lane), electrophoresed,
blotted and hybridized to the b1-subunit of Na+,K+-ATPase or to hamster
b-actin. This experiment has been repeated twice producing similar resultsNa+,K+-ATPase expression in prostate cancer 31
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Androgen regulation of Na+,K+-ATPase expression in
LNCaP-FGC cells
Because androgen regulation of the expression of the b1-subunit
of Na+,K+-ATPase was a new finding, this was investigated in
more detail. When R1881 (0.1 nM) was added for different time
periods to LNCaP-FGC cells in culture, b1 mRNA expression
became markedly down-regulated after relatively long incubation
times (24 h, Figure 3). Maximal down-regulation of b1-subunit
mRNA expression started at R1881 concentrations between
0.01 nM and 0.03 nM (after 24 h). These concentrations are in the
same range as the concentrations which are needed for initiation of
PSA mRNA up-regulation by the androgen receptor (Murtha et al,
1993) (Figure 4).
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Figure 2 Expression of the b1-subunit of Na+,K+-ATPase in androgen-responsive and androgen-independent human prostate cancer xenografts. Xenografts
were dissected from mice and immediately frozen in liquid nitrogen. Total RNA was isolated and loaded on a denaturing gel (20 mg per lane), electrophoresed,
blotted and hybridized to the b1-subunit of Na+,K+-ATPase. Ethidium bromide staining of the RNA revealed that there were no differences in loading of the RNA
samples. The xenografts were scored for androgen-responsive (yes) or androgen-independent growth (no), and for degree of glandular differentiation (++ =
well; + = moderately-well; +/– = moderate; – = poor; + and – = both moderately-well and poorly differentiated glandular tissue in one xenograft) (van Weerden et
al, 1996)
Figure 3 Time course of androgen-induced down-regulation of b1-subunit of Na+,K+-ATPase mRNA expression. LNCaP-FGC cells were cultured for 0–96 h in
the absence or presence of 0.1 nM R1881. Total RNA, isolated as indicated in Materials and Methods, was loaded on a denaturing gel (20 mg) and
electrophoresed, blotted and hybridized to the b1-subunit of Na+,K+-ATPase or hamster b-actin. This experiment has been repeated three times producing
similar results
Figure 4 Regulation of b1-subunit of Na+,K+-ATPase expression at different androgen concentrations. LNCaP-FGC cells were cultured for 24 h in the absence
or presence of 0.003–10 nM R1881. Total RNA, isolated as indicated in Materials and Methods, was loaded on a denaturing gel (20 mg) and electrophoresed,
blotted and hybridized to the b1-subunit of Na+,K+-ATPase, PSA or hamster b-actin. This experiment has been repeated three times producing similar results
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In epithelial cells usually the a1- and b1-subunit form the active
Na+,K+-ATPase (Lingrel and Kuntzweiler, 1994). Therefore, a goat
polyclonal antibody directed against purified rabbit kidney
Na+,K+-ATPase was used to detect a1- and b1-subunits of
Na+,K+-ATPase in the same cell homogenate. It was observed that
the b1-subunit protein was markedly down-regulated in LNCaP-
FGC cells after 6 days of culture in the presence of androgens
(0.1 nM), while expression of the a1-subunit protein level
remained unchanged (Figure 5).
Cardiac glycosides like ouabain cannot enter cells. Their action
on Na+,K+-ATPase activity can only occur because these
compounds bind with a relatively high specificity to the extracel-
lular domain of the a-subunit which is stabilized in the membrane
by the b-subunit (Charlemagne, 1993; Mercer, 1993). Ouabain
0 days 3 days 6 days
Alpha 1
b1
118 kDa
86 kDa
51 kDa
34  kDa
Figure 5 Androgen regulation of Na+,K+-ATPase protein expression. LNCaP-FGC cells were cultured for 0, 3 or 6 days in the presence of 0.1 nM R1881. The
cells were lysed in Laemmli sample buffer, and 5 mg protein was loaded on each lane of the gel, electrophoresed for 1 h at 200 V and blotted. Specific detection
of a1- and b1-subunit Na+,K+-ATPase was performed as outlined in the Materials and Methods section. The molecular mass markers are indicated on the right.
Due to glycosylation, the b1-subunit appears as a broad protein band between the 51 and 34 kDa markers. This experiment has been repeated twice producing
similar results.
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Figure 6 Androgen regulation of the expression of Na+,K+-ATPase in the membrane. For the Scatchard analysis of 3H-ouabain binding to Na+,K+-ATPases
expressed in the membrane, LNCaP-FGC cells were cultured to 50% confluence in the presence (s) or absence (l) of 0.1 nM R1881. After 6 days the medium
was replaced for incubation buffer containing 3H-ouabain (2.5 nM, 5 nM, 10 nM, 20 nM, 40 nM, 80 nM) in the presence or absence of 500-fold non-labelled
ouabain. Cells were incubated for 2 h at 37°C. Subsequently, the cells were harvested and radioactivity was measured. This experiment has been repeated
twice producing similar resultsNa+,K+-ATPase expression in prostate cancer 33
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binding will result in decreased activity of Na+,K+-ATPase.
However, radioactively labelled ouabain can also be used to
measure the amount of Na+,K+-ATPase expressed in the
membrane. In order to do so in control or R1881 pretreated
(6 days) LNCaP-FGC cells, these cells were incubated with
different concentrations of 3H-ouabain in the presence or absence
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Figure 7 In contrast to ouabain-induced inhibition of Na+,K+-ATPase, androgen-induced down-regulation of Na+,K+-ATPase does not result in protection
against cisplatin-induced prostate cancer cell death. (A) Cells were cultured for 8 days in the presence of different concentrations (0, 0.025, 0.05, 0.1, 0.25, 0.5
and 1 mM) of the specific inhibitor of Na+,K+-ATPase, ouabain. Cell viability was measured using the NBT assay, as described in Materials and Methods (panel
A). (B) LNCaP-FGC cells were cultured for 2 h in the absence (black bars) or presence (shaded bars) of 100 nM ouabain before different concentrations
cisplatin were added to the culture medium (0, 20, 30, 35, 40, 45, 50 and 60 mM). After 8 days the cells were harvested and DNA measured as indicated in the
Materials and Methods section (panel B). (C) LNCaP-FGC cells were cultured for 6 days in the absence (black bars) or presence (shaded bars) of 0.1 nM
R1881. Subsequently different concentrations cisplatin were added to the culture medium (0, 20, 30, 35, 40, 45, 50 and 60 mM), and culture was continued for 8
days. Cells were harvested and DNA was measured as indicated in the Materials and Methods section (panel C). These experiments were repeated at least
twice producing similar resultsof 500-fold non-labelled ouabain for a short period of time
(Figure 6). Scatchard analysis on living cells revealed a Kd of
78 nM in the control situation and 91 nM in case of R1881 pretreat-
ment. The Bmax value of control cells was 4.9 pmol mg—1 protein
and about fourfold higher than the Bmax of R1881 pretreated cells
(1.2 pmol mg—1 protein). These data are in line with the observa-
tions described in Figure 5, and indicate that androgen-induced
down-regulation of the b1-subunit protein expression is rate-
limiting for the expression of the a,b-heterodimer of Na+,K+-
ATPase at the cell surface (as measured by 3H-ouabain binding).
Inhibition of cisplatin-induced cell death
Cisplatin induces cell death in most culture systems. It was
observed that cisplatin induces apoptosis at 40 mM and 70 mM and
induces necrosis at much higher concentrations (500 mM; data not
shown). In all further experiments we have used cisplatin at
concentrations below 70 mM.
Cisplatin accumulation in the cell is partly dependent on the
K+ influx; when the K+ gradient is steep, cisplatin will enter the
cell relatively easy (Andrews et al, 1991). The K+ gradient is
generated by Na+,K+-ATPase, and there are several indications that
reduced expression or activity of Na+,K+-ATPase will result in
reduced uptake of cisplatin (Andrews et al, 1991; Shinohara et al,
1994; Ohmori et al, 1994; Kasahara et al, 1996; Bando et al, 1997,
1998a, 1998b). For prostate cancer the relation between expres-
sion or activity of Na+,K+-ATPase and effectiveness of cisplatin
treatment has not been investigated to this point.
One way to inhibit Na+,K+-ATPase activity specifically is to
culture LNCaP-FGC cells in the presence of ouabain. However,
the concentration of ouabain should be low because otherwise the
Na+/K+ homeostasis becomes too severely disrupted and the cells
will die. In order to investigate which concentration of ouabain
could be used, LNCaP-FGC cells were cultured in the presence
of different concentrations of ouabain and cell viability was
measured. It was observed that a concentration of 100 nM ouabain
would only marginally reduce viability of the cells (Figure 7A).
Next, it was observed that LNCaP-FGC cells cultured in the
presence of 100 nM ouabain were much more resistant to cisplatin-
induced apoptosis than control cells at cisplatin concentrations of
20—50 mM (Figure 7B). The next step was to culture LNCaP-FGC
cells in the presence of 0.1 nM R1881 for 6 days (Na+,K+-ATPase
expression becomes reduced), followed by treatment with
different concentrations of cisplatin for 1 week. In contrast to the
decrease in Na+,K+-ATPase activity by ouabain, androgen-induced
down-regulation of expression of Na+,K+-ATPase did not result
in a clear protection against cisplatin-induced prostate cancer
cell death. This suggests that potentially other androgen-induced
import-mechanisms are counteracting the effect of androgen-
induced down-regulation of Na+,K+-ATPase on cisplatin-induced
cell death.
DISCUSSION
Regulation of expression of Na+,K+-ATPase in prostate
cancer
Na+,K+-ATPase is necessary for the maintenance of sodium
and potassium homeostasis in eukaryotic cells. Regulation of
Na+,K+-ATPase activity can be achieved by various routes:
intracellular Na+ concentration is an important regulator, the
abundance of the subunits can be controlled by transcriptional or
post-transcriptional regulation (aldosterone in kidney and thyroid
hormone in myocardium) (Hensley et al, 1992; Wheling et al,
1993; Ewart and Klip, 1995; Middleton, 1996), but it is also
possible to regulate activity of the a-subunit by binding of
inhibitors as ouabain and bufalin (MacGregor and Walker, 1993).
Recently, the promoter of the b1-subunit of Na+,K+-ATPase
was shown to contain several mineralocorticoid and glucocorti-
coid responsive elements (MRE/GRE) (Derfoul et al, 1998). When
a large portion of the promoter region (—1141 to +490) was cloned
in front of a luciferase reporter gene, profound up-regulation of
transcriptional activity was found in the presence of glucocorticoid
receptors in CV-1 cells. It is true that androgen receptors and
glucocorticoid receptors can bind to similar responsive elements
on DNA (Van Dijck et al, 1989). However, there are also distinct
differences between the two receptors which contribute to
receptor-selective transcriptional regulation (Rundlett and
Miesfeld, 1995; Claessens et al, 1996; Scheller et al, 1998). It is
interesting that, in contrast to the findings of Derfoul et al (1998),
in the current investigations androgens are potent inhibitors of the
expression of the b1-subunit of Na+,K+-ATPase in LNCaP cells. At
the basis of the difference in regulation of b1-subunit mRNA
expression by glucocorticoid and androgen receptors may be
distinct receptor differences, but promoter and cell context (CV-1
vs LNCaP) may also play an important role.
Down-regulation of the b1-subunit of Na+,K+-ATPase is much
more pronounced in the androgen-dependent LNCaP-FGC cells
than in androgen-independent LNCaP-LNO cells. In other words,
the b1-subunit of Na+, K+-ATPase is expressed at higher levels in
androgen-independent LNCaP-LNO cells cultured in the presence
of androgens than in androgen-dependent LNCaP-FGC cells
cultured under similar conditions. This observation was also
done in human prostate cancer xenografts: androgen-independent
xenografts express higher levels of the b1-subunit of Na+,K+-
ATPase than androgen-responsive xenografts when grown in the
presence of testosterone. The only exception is xenograft
PC-135 which seems to express low levels of b1-subunit mRNA.
Because of these findings it may be of interest to investigate
whether gain of expression of the b1-subunit of Na+,K+-ATPase
can be used as a molecular marker to distinguish between
androgen-dependent and androgen-independent prostate cancer
cells in biopsy material from patients who have not been treated
by androgen ablation therapy. Another point of interest is that
chromosomal localization of the b1-subunit of Na+,K+-ATPase
on 1q24—25 is in the same region as the putative prostate
cancer-susceptibility locus HPC1 (Cooney et al, 1997).
Inhibition of cisplatin-induced cell death
Cisplatin is a chemotherapeutic agent that has been used
experimentally as adjuvant therapy in the treatment of hormone
refractory prostate cancer; the effectiveness of this treatment has
always been limited (Akimoto et al, 1994; Coughlin et al, 1994;
Sakai et al, 1994; Veronesi et al, 1996). In the current investigation
it is shown that the chemotherapeutic effectiveness of cisplatin
treatment of a prostate cancer cell line is affected by Na+,K+-
ATPase activity. When Na+,K+-ATPase activity is reduced using
ouabain as a specific inhibitor, the sensitivity to cisplatin-induced
cell death is reduced. Surprisingly, when the prostate cancer cells
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ATPase, cisplatin-induced cell death was only marginally affected.
An explanation could be that in LNCaP-FGC cells other androgen-
regulated mechanisms are counteracting the effect of reduced
Na+,K+-ATPase expression on cisplatin-induced apoptosis. In
small-cell lung cancer cells the importance of Na+,K+-ATPase as
an active transporter of cisplatin was also found to be limited, indi-
cating that also in these cells other mechanisms of cisplatin trans-
port are operational (Bando et al, 1998a, 1998b).
Thus far, cisplatin treatment of hormone refractory prostate
cancer patients has not been very effective. Here we show that
down-regulation of Na+,K+-ATPase can, under certain circum-
stances, further reduce the effectiveness of cisplatin treatment of
prostate cancer cells. If, however, a method could be developed to
increase Na+,K+-ATPase expression in prostate cancer cells, it
should, at least in theory, be possible to increase the effectiveness
of cisplatin as adjuvant treatment against hormone refractory
prostate cancer.
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